We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
+147%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
–
AUM
$96.9M
AUM Growth
+$51.9M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNCE
1
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$89.3M 92.14%
10,230,349
– –
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$7.62M 7.86%
2,790,964
– –

Similar funds

IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
VM
Value Monitoring Menlo Park, California $1.5M AUM 13.21% 1-Year Est. Return
CL
CRV LLC Palo Alto, California $1.56M AUM 87.36% 1-Year Est. Return
GAM
GVO Asset Management Zug, Switzerland $1.07M AUM 24.36% 1-Year Est. Return
MC
Manteio Capital Jersey City, New Jersey $1.05M AUM
NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
HCIG
H Capital II GP Grand Cayman, Cayman Islands $1.83M AUM
NP
Nimble Partners San Francisco, California $556K AUM 61.7% 1-Year Est. Return

TRV GP II's Q4 2019 Portfolio in Review

As of Q4 2019, TRV GP II held 2 positions worth $96.9M, up 115% from $45.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2019: portfolio turnover was 0%. TRV GP II opened no new positions and made no exits, leaving the 2-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's ten largest holdings make up 100% of its $96.9M portfolio in Q4 2019.
  • TRV GP II opened 0 new positions and closed 0 in Q4 2019.
  • TRV GP II's portfolio value rose 115% quarter-over-quarter to $96.9M.

Based on TRV GP II's 13F filing for Q4 2019, filed 5 Feb 2020.